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Telomeres are located at the end of chromosomes and consist of DNA tandem repeats that recruit the specialized 
protein complex “shelterin”. Shelterin has a crucial role in controlling chromosome end protection, telomere 
recombination and telomere length. Telomeres shorten with every cell division, finally leading to 
telomere-dysfunction and the induction of senescence or apoptosis. Cancer formation is paralleled by a change in 
telomere regulation. Re-activation of telomerase ensures the maintenance of telomere function to facilitate 
unlimited proliferative potential. Importantly, aberrant function of the shelterin complex contributes to tumor 
formation and genomic instability in human cancer. miRNAs are important regulators of central cancer 
pathways and are of high clinical relevance. We recently showed that the onco-microRNA miR-155 controls the 
expression of TRF1 in human breast cancer to promote increased telomere fragility and genomic instability. 
Importantly, low TRF1 expression correlates with poor prognosis in estrogen receptor positive cancer patients, 
underlining the clinical relevance of miR-155 dependent regulation of TRF1 in human breast cancer. Our work 
suggests the existence of a network of miRNAs that controls telomere function in telomere related pathologies. 
Identification and functional validation of “telo-miRNAs” is expected to open new avenues in the understanding 
of telomere related maladies such as cancer and aging. 
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Vertebrate telomeres consist of TTAGGG tandem repeats 
that recruit the specialized protein complex “shelterin” 
[1,2]
.
Shelterin controls various aspects of telomere function and 
consists of six core components. TRF1 and TRF2 bind 
double stranded telomeric DNA and POT1 binds to the 
single stranded telomeric 3’overhang 
[2-5]
. The DNA binding
shelterin proteins interact with RAP1, TPP1 and TIN2 to 
form a functional complex. TRF1, TRF2 and POT1 have a 
key role in telomere protection by suppressing the activation 
of the DNA damage signaling and repair pathways at 
chromosome ends 
[5-7]
. In addition, shelterin controls
telomere length and the frequency of homologous 
recombination between telomeric sister chromatids 
[2, 8]
.
Telomeres shorten with each cell division, unless the reverse 
transcriptase telomerase replenishes chromosome ends 
[1]
.
Critical telomere shortening provokes telomere dysfunction 
and the activation of a DNA damage response at 




The escape from replicative senescence is a key step in 
tumorigenesis and is achieved by the reactivation of 
telomerase activity, as observed in 90% of human cancers 
[12]
. A growing body of evidence suggests that shelterin
complex components can play a central role during cancer 
formation or progression. Recurrent POT1 mutations linked 
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to telomeric and chromosomal abnormalities have been 
identified in chronic lymphocytic leukemia (CLL) 
[13]
. 
Wnt/-catenin signaling drives TRF2 expression to improve 
telomere function in cancer cells 
[14]
. Finally, loss of TRF1 
results in chromosome fragility at telomeres and increased 
cancer formation in the absence of p53 
[6,7]
. Together, these 
findings indicate that understanding mechanisms that control 
the expression of telomerase or shelterin components during 
cancer formation is of high relevance.  
miRNAs are crucial modulators of gene expression that 
act across multiple oncogenic pathways and serve as efficient 
prognostic and predictive biomarkers 
[15]
. Although telomere 
function is a central aspect in cancer and aging, miRNAs that 
impact on the regulation of telomere function in human 
cancer have been identified only very recently. Spurred by a 
possible direct therapeutic application, a panel of miRNAs 
was identified that target the catalytic subunit of telomerase, 
hTERT 
[16-20]
. In particular, miR-138, miR-498, miR-1207-5p 
and miR-1266 were able to reduce cancer cell proliferation, 
phenocopying the effect of classic RNAi mediated 
knock-down of TERT 
[17-20]
. However, among all reported 
miRNAs targeting hTERT only miR-1266 was found to have 
clinical relevance, as demonstrated by the negative impact of 




In our recent study we aimed to identify clinically relevant 
miRNAs that control the expression of shelterin components 
[21]
. We found that miR-155 efficiently represses the 
translation of TRF1 in cell lines derived from different 
cancer types. miR-155 is a potent onco-miRNA that is 
involved in leukemia, breast, colon and lung cancer 
[22-26]
. 
miR-155 is efficiently up-regulated in luminal, HER2
+
 and 
triple negative breast cancer subtypes. Importantly, miR-155 
upregulation correlates with low TRF1 protein expression 
levels in luminal breast cancer specimen, supporting a role 
for miR-155 in regulating TRF1 expression. Low TRF1 
expression levels lead to a significantly reduced distant 
metastasis-free survival and relapse-free survival of estrogen 
receptor positive luminal breast cancer patients. Importantly, 
this effect is recapitulated by a panel of validated miR-155 
target genes, indicating that miR-155 dependent regulation of 
TRF1 represents a clinically relevant aspect of the oncogenic 
potential of miR-155. Studies using genetic mouse model 
systems demonstrated that loss of TRF1 affects telomere 
protection, telomere replication, and promotes 
tumor-formation in the absence of p53 
[6, 7]
. This highlights 
the role of TRF1 as tumor suppressor and regulator of 
genomic stability. Using breast cancer model cell lines we 
found that miR-155 controls telomere function and 
homeostasis by limiting the expression of TRF1. In 
particular, miR-155 increases the frequency of chromosome 
fragility at telomeric repeats, promotes telomeric sister 
chromatid fusions and drives telomere dysfunction as 
indicated by a recruitment of DNA damage factors at 
chromosome ends. Consistent with the role of TRF1 as 
negative regulator of telomere length, reducing TRF1 
expression by ectopic introduction of miR-155 mediates 
telomere elongation 
[27-30]
. Together, this demonstrates that 
miR-155 can promote genomic instability by impairing 
telomere function in human breast cancer. These data show 
for the first time that miRNAs can modulate shelterin 
function in human cancer and suggest the existence of 
additional “telo-miRNAs” that can link key-events in 
oncogenesis with telomere function and homeostasis. 
Telomere dysfunction has been identified as metastasis 
promoting event in prostate cancer but was also 
demonstrated to impair the functionality of stem cells by 
driving senescence, a hallmark of organismal aging 
[31,32]
. In 
addition, accumulation of short telomeres has a negative 
impact on longevity 
[33]
. The central role of shelterin in 
chromosome end protection and telomere length regulation 
suggest that alterations in telo-miRNA expression might not 
only have long-term effects on telomere homeostasis in 
cancer cells but also in differentiated cells or adult stem cells. 
Consequently, it is tempting to speculate that “telo-miRNAs” 
can modulate telomere homeostasis during ontogenesis and 
impact on organismal aging and telomere related pathologies. 
The discovery that “telo-miRNAs” can control telomere 
function and homeostasis has introduced a new level of 
telomere regulation. Future work will aim to identify 
additional functionally relevant telo-miRNAs, discover 
pathways that regulate telo-miRNA expression and link 
telo-miRNAs to key biological processes related to cancer 
formation or aging. 
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